Haynes and Boone’s Pharmaceuticals Industry Group provides experience in pharmaceuticals, biotechnology and biosimilars at the intersection of the pharmaceutical, biotechnology, drug delivery and medical device arts. Our attorneys have vast and varied experience in pharmaceuticals and can meet clients’ intellectual property, regulatory and compliance, and business transaction needs. We represent a wide array of emerging growth, middle stage and Fortune 100 companies in the pharmaceutical industry, and have a knowledge base and skill set that is particularly helpful to our clients in this field. Our practitioners represent clients in technology areas such as:
- Pharmaceutical compounds, compositions, formulations, and methods for the treatment, diagnosis, screening for, and prevention of various cancers, viral and bacterial infections, dementia, substance dependency, and cardiovascular, ocular, neurological, and dermatological diseases, conditions, and symptoms related thereto, including solid and liquid oral formulations, injectables, intranasal sprays, transdermal substrates, and other routes of administration
- Represented a major pharmaceutical company in connection with in-licensing Phase 3 compounds and joint control of testing and approval process.
- Represented a major pharmaceutical company in connection with a long-range joint development and marketing collaboration.
- Represented a major pharmaceutical company in connection with multiple copromotion agreements.
After just three months at Haynes and Boone, LLP, Partner Randy Peak has been named Co-Chair of the firm’s Healthcare and Life Sciences Practice Group. Randy joined the firm in August, supporting the Healthcare, Life Sciences and Pharmaceuticals Practice Groups and Precision Medicine and Digital Health group. He serves alongside Bill Morrison to co-lead the national healthcare practice. “In just [...]